Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam

Heiligenberg, Marlies; Michael, Kristina M.; Kramer, M A; Pawlita, Michael; Prins, Maria; Coutinho, Roel A.; Dukers-Muijrers, Nicole H. T. M.; Waterboer, Tim

doi:10.1097/olq.0b013e3181e71069

Cited by 35 publications

(29 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prevalence of antibodies against HPV-16, which is the most carcinogenic and therefore most important HPV type, was high compared to other studies among (mostly heterosexual) males (16,17,34,41), but comparable to data reported for MSM specifically (40,42). However, comparisons between HPV serology studies are hampered by major differences in characteristics of the study population and in serology methods.…”

Section: Discussionmentioning

confidence: 47%

Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study

Mooij

Klis

Sande

et al. 2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Men who have sex with men (MSM), in particular HIV-infected MSM, are at increased risk for diseases related to human papilloma virus (HPV). Our goal was to assess the effect of HIV status on the presence of type-specific antibodies against seven high-risk HPV types in HPV-unvaccinated MSM. Moreover, we compared determinants of HPV seropositivity between HIV-negative and HIV-infected MSM.Methods: MSM !18 years of age were recruited from the Amsterdam Cohort Studies, a sexually transmitted infection clinic, and an HIV-treatment center in Amsterdam, the Netherlands. Participants completed a riskfactor questionnaire; serum samples were analyzed using a fluorescent bead-based multiplex assay.Results: MSM (n ¼ 795) were recruited in 2010 to 2011; 758 MSM were included in this analysis. Median age was 40.1 years (interquartile range 34.8-47.5) and 308 MSM (40.6%) were HIV-infected. Seroprevalence of HPV-16 was 37.1% in HIV-negative and 62.7% in HIV-infected MSM (P < 0.001); seroprevalence of HPV-18 was 29.1% in HIV-negative MSM and 42.5% in HIV-infected MSM (P < 0.001). Similar patterns of seroprevalence were observed for HPV types 31, 33, 45, 52, and 58. In multivariable analyses, HPV seropositivity was associated with HIV infection [adjusted OR ¼ 2.1; 95% confidence interval, 1.6-2.6]. In multivariable analyses stratified by HIV status, increasing age and number of lifetime male sex partners were significantly associated with HPV seropositivity in HIV-negative, but not HIV-infected MSM.Conclusions: Seroprevalence of high-risk HPV types is high among unvaccinated MSM. Impact: HIV infection is a strong and independent determinant for HPV seropositivity, which we hypothesize is because of increased persistence of HPV infection in HIV-infected MSM. Cancer Epidemiol Biomarkers Prev; 22(10); 1698-708. Ó2013 AACR.

show abstract

Section: Discussionmentioning

confidence: 47%

Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study

Mooij

Klis

Sande

et al. 2013

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…More recent publications have highlighted the importance of age of sexual debut, [8] marital status, [29] high number of lifetime sexual partners, [5,30,31] number of recent sexual partners, [30] longer history of sexual activity, [30] route of exposure, [26,30,32] and having sex with men [32][33][34] as risk factors for anogenital HPV infection. Similar observations about sexual risk behaviour and an association with HPV have been made in studies of men in SSA.…”

Section: Factors Associated With Hpv Infectionmentioning

confidence: 99%

“…[17,36,38,39] Related findings from the trial in Kenya have highlighted less frequent bathing as a risk factor for HPV infection, which may be associated with poor genital hygiene in uncircumcised men. [18,28] STIs are independently associated with the risk of HPV infection, particularly chlamydia, [19,30] herpes simplex virus (HSV)-2, [34] and hepatitis B. [40] While they may share a common mode of transmission, STIs are thought to increase the risk of HPV infection by facilitating access to the basal epithelium through micro-abrasions in the skin.…”

Section: Factors Associated With Hpv Infectionmentioning

confidence: 99%

Human papillomavirus infection and disease in men: Impact of HIV

Delany‐Moretlwe

Chikandiwa

Gibbs

2013

South. Afr. j. HIV med.

View full text Add to dashboard Cite

There is growing evidence of a significant burden of human papillomavirus (HPV) infection and associated disease in men. High rates of HPV infection have been observed in men from sub-Saharan Africa where HIV prevalence is high. HIV infection increases HPV prevalence, incidence and persistence and is strongly associated with the development of anogenital warts and anal, penile and head and neck cancers in men. Despite increasing access to antiretroviral therapy, there appears to be little benefit in preventing the development of these cancers in HIV-positive men, making prevention of infection a priority. New prevention options that are being introduced in many African countries include male circumcision and HPV vaccination. However, more data are needed on the burden of HPV disease in men before boys are included in HPV vaccination programmes. Human papillomavirus (HPV) is a common sexually transmitted infection (STI) affecting both men and women. S Afr J HIV Med[1] HPV infections can be classified as either low-(LR) or high-risk (HR).[2]HR-HPV infections have been associated with cancer of the anogenital and oropharyngeal tissues. While the majority of HPV infections are transient and clear spontaneously, persistent infection with HR-HPV is associated with the development of pre-neoplastic and neoplastic lesions in these areas (Fig. 1). While much is known about the natural history of HPV infection in cervical cancer in women, less is known about the development of HPV-associated disease in men. Emerging evidence points to a significant role for HIV infection in promoting HPV prevalence, incidence and persistence. This review provides an update on current evidence regarding the epidemiology of HPV infection and disease in men, the effects of HIV on HPV infection and disease in men in sub-Saharan Africa (SSA), and the prospects for prevention in this setting. Global burden of HPVHPV infection is ubiquitous in men. A systematic review of 62 studies using reliable methods of HPV DNA detection and conducted prior to 2009, representing 14 800 men in 23 countries, showed that anogenital HPV DNA prevalence is generally high in sexually active men. The review highlighted considerable variation in estimates by region, from 1% to 84% in LR men, to 2% to 93% in HR men. [3] Compared with studies in women, peak prevalence spanned a wide range of ages, suggesting that men have the potential for longer-term persistence of infection or higher rates of re-infection.[3] Typespecific HPV seroprevalence studies are better indicators of lifetime exposure to HPV infection, although they may underestimate cumulative HPV exposure, given that not all infections lead to seroconversion.[4] Recent population-based studies have estimated the prevalence of antibodies to vaccinepreventable HPV types 6, 11, 16 and 18. Among men aged 14 -59 years in the USA, 12.2% of men were seropositive for any vaccine type, with a peak prevalence of 18% among men aged 50 -59 years.[5] In a similar population-based study in Australia, peak prevalence of any...

show abstract

“…[12] The quadrivalent vaccine has demonstrated efficacy in the prevention of cervical, vulvar and vaginal cancer, genital warts and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18 in females, [10] and estimates show that, as well as being potentially cost effective, [13] national vaccination programmes targeting adolescent females and young women can be expected to result in decreased incidences of HPV infection [14] and genital warts, [15] in both females and heterosexual males (HM) as a result of herd immunity. [15] However, no change was predicted for men who have sex with men (MSM; a group with a high prevalence of HPV infection [16] ) or females outside the age range for vaccination. [15] Various arguments exist in favour of nationwide vaccination of males as well as females, including the increased likelihood of herd immunity, increased effect in the MSM population and decreased incidence of HPV-associated disease in males (potentially more so than is associated with decreased transmission of the virus from females).…”

Section: Most Common Adverse Events (≥5% Of Males Aged 9-26 Years Recmentioning

confidence: 99%

“…Features and properties of the quadrivalent human papillomavirus (HPV) types 6,11,16,18 vaccine (Gardasil®)…”

mentioning

confidence: 99%

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males

Garnock-Jones¹,

Giuliano

2012

Drugs R D

View full text Add to dashboard Cite

The quadrivalent HPV types 6, 11, 16, 18 vaccine (Gardasil ® ) is a recombinant vaccine comprising purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18.The vaccine was highly immunogenic. Geometric mean titres (GMTs) and seroconversion rates for all four HPV types at month 7 in males aged 10-15 years were noninferior to those in females aged 16-23 years, and those in males aged 9-15 years were noninferior to those in females aged 9-15 years. In addition, GMTs and seroconversion rates in males aged 16-26 years receiving the vaccine were higher than those receiving amorphous aluminium hydroxyphosphate sulfate adjuvant (AAHS) control.The quadrivalent HPV vaccine was significantly more effective than AAHS control at decreasing the incidence of HPV 6-, 11-, 16-or 18-related external genital lesions (primary endpoint) in a randomized, double-blind, placebo-controlled, multicentre study in males aged 16-26 years. The most common clinical endpoint was HPV 6-and 11-related condyloma; efficacy was robust against these lesions.The vaccine is also expected to be protective against genital warts in males aged 9-15 years, as the immune response in males of this age group was noninferior to that in males aged 16-26 years.The quadrivalent HPV vaccine was generally well tolerated in males aged 9-26 years. The most common adverse events reported were injection-site related, and most of these were of mild to moderate severity.Correspondence: Karly P. Garnock-Jones, Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz. DisclosuresThe preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. HHS Public Access Author manuscriptDrugs. Author manuscript; available in PMC 2015 November 11. Published in final edited form as:Drugs. 2011 March 26; 71(5): 591-602. doi:10.2165/11205980-000000000-00000. Author Manuscript Author ManuscriptAuthor Manuscript Author ManuscriptFeatures and properties of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine (Gardasil®) Featured indicationPrevention of genital warts (condyloma acuminata) caused by infection with HPV types 6 and 11 in males aged 9-26 y Vaccine compositionVirus-like particles (VLPs) derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18Formulated with a proprietary amorphous aluminium hydroxyphosphate sulfate adjuvant (225 μg per dose) Dosage and administrationRoute of administration Intramuscular injection Dose 0.5 mL (containing 20, 40, 40 and 20 μg of VLPs for HPV types 6, 11, 16 and 18, respectively)Administration schedule Three-dose regimen; injections at months 0, 2 and 6Most common adverse events (≥5% of males aged 9-26 years receiving the quadrivalent HPV vaccine)Injectio...

show abstract

Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam

Abstract: Prevalence of 8 hrHPV antibodies was high in the Amsterdam population, especially in MSM.

Cited by 35 publications

References 42 publications

Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study

Seroepidemiology of High-Risk HPV in HIV-Negative and HIV-Infected MSM: The H2M Study

Human papillomavirus infection and disease in men: Impact of HIV

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males

Contact Info

Product

Resources

About